Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Stopped Terminated (Due to small number of ongoing patients. Patients ongoing at time of termination could choose to join study D-FR-01072-004 for long term follow-up.

Conditions

• Neuroendocrine Tumors

Interventions

• DRUG: Satoreotide tetraxetan
• OTHER: Amino acid solution
• OTHER: Antiemetic

Sponsor

Ipsen